Who Pays for a First-in-Class Stem Cell Therapy
NHS access decisions are documented in public — and almost impossible to read. The answer to "who pays for this, and what has to happen first" is spread across NHS England long-reads, statutory guidance, contract service conditions, planning frameworks and pricing schedules. Most of it changes every April. None of it is written for someone in a hurry.
Curated AI Research is my attempt to close that gap. Each briefing takes one question — how a therapy gets funded, whose budget it lands on, what a tender actually covers — and answers it end to end: the named mechanism, the clause or fund it sits in, the people who have to sign it off, and what usually goes wrong.
AI does the retrieval and the first pass. Every material claim is then traced back to a primary source and cited, so you can check it rather than take it on trust. What the briefings argue, what they leave out and what they say matters is mine — drawn from a career in UK pharmaceutical market access and specialty medicines.
They are written for people who have to act on this: commercial, market access and medical teams preparing a launch; colleagues explaining a funding pathway to a finance director; and anyone who needs to know the difference between a policy that persuades and a clause that compels.
Free to read, sourced throughout, and current at the date on the page. Not advice — a map..
The Same skill set that draws the map delivers the launch
Asking the right question of a system is the first half of the job. The second half is doing something about the answer: building the account plan, getting a desigws the map delivers the launchnated centre activated, finding the budget the pathway cost actually falls into, and getting the procurement paperwork through before it becomes the reason a patient waits.
They are the same skill. The briefings are what it looks like on the page; commercialisation is what it looks like in the field — a funding decision converted into treated patients, centre by centre.
That is what Healthcare Acumen does.
Who Pays for CVD Secondary Prevention?
NHS funding decisions for cardiovascular secondary prevention are documented in public and almost impossible to read as a whole — the answer to "who pays for this, and what has to happen first" is scattered across a Drug Tariff part number, a service condition in the NHS Standard Contract, a QOF indicator that changed in April, a scoring metric in the oversight framework and a modern service framework published in July. This briefing takes one question and follows it end to end: what happens to a new lipid-lowering therapy after NICE says yes — whose budget the cost lands on, which committee lists it and under which clause, what actually gets tendered locally, and what determines whether any of it becomes treated patients.
Inclisiran is the worked example, because five years of public evidence show what central funding and a Drug Tariff listing bought and what they did not. The questions are the same ones a launch has to answer in the field, which is the point: that priority 7 of the CVD framework, QOF CHOL004 and the oversight metric are one number with one definition is a research finding on the page,
But in an account plan it is the argument that reaches the ICB medical director, the finance director and the practice on a single slide — and turning the mechanism into the account plan, the formulary submission, the funding conversation and the tender response is the work I do at Healthcare Acumen.
Every figure is traced to a primary source and linked; what could not be verified is listed at the end. Not advice — a map.
Healthcare- Acumen
Washingborough, Lincolnshire, England, United Kingdom